 n committees
 șThe value cap was increased from 4x to 5x the Base Value Cap at the time of grant for the Chair 
of the Board
Changes for Executive Management
Short-term incentive (STI) 
opportunity șCEO target percentage was increased from 75% to 100% of fixed annual base salary.
 șTarget for other members of Executive Management was increased from 50% to 75% of fixed annual base 
salary.
 șMaximum bonus potential for the CEO was adjusted from 100% to 150% of the fixed annual base salary.
 șMaximum bonus potential for other members of Executive Management was adjusted from 75% to 
100% of fixed annual base salary.
Long-term incentive (LTI) 
grant: șRemoved warrants as an instrument and introduced a grant of PSUs and RSUs with a 50 ­50 split.
Long-term incentive (LTI) 
grant value cap șCEO grant value cap was increased from 250% to 400% of the fixed annual base salary at the time of grant. 
 șFor other members of Executive Management, the value cap remains at 250% of the fixed annual ba e 
salaryPension 
cont.Other 
 benefitsCash 
bonusSeverance 
payLTIP – RSU 
value at 
grantLTIP – PSU 
value at 
grantTotal 
Remune -
rationSplit 
fixed vs. 
variable
2024 
Remuneration to Executive 
Management
Adam Sinding Steensberg 9,000 1,800 276 12,150 15,324 15,324 53,874 21% / 79%
Henriette Wennicke 4,500 900 311 4,500 4,789 4,789 19,789 29% / 71%
Total EM 13,500 2,700 587 16,650 20,113 20,113 73,663 23% / 77%
Other Corp. Management 11,746 1,404 1,101 11,869 3,347 15,084 15,084 59,635 24% / 76%
 
Total 25,246 4,104 1,688 28,519 3,347 35,197 35,197 133,298 23% / 77%
1 Detailed information about Board and Management remuneration prior to 2024 can be found in the company’s Remuneration and Annual Reports for previous years.and composition of remuneration to Corporate Management. 
In addition, the company’s performance during the year has 
led to above target bonus payouts. 
Remuneration to Corporate Management in 2024 was 
DKK 133.30 million compared to DKK 63.04 million in 2023. 
 s of Management are assigned individual bonus 
targets, designed to support Zealand Pharma’s business 
strategy, encompassing both short ­ and long ­term value 
creation. These targets, set as a percentage of the indi ­
vidual annual base salary, are in line with the company’s 
Remuneration Policy. The actual disbursement of short ­term 
bonuses is contingent upon the achievement of predefined perfor ­
mance targets.
Performance targets (or KPIs) are carefully considered and 
set by the Board each year to align with the overall long ­term 
strategy and support its ambitions as a company. 
After careful review, the short ­term incentive opportunities 
for Management were adjusted in 2024. The CEO may 
receive a target of 100% of annual base salary in the short ­
term incentives with a maximum payout factor of 150%. 
For other members of Executive Management and Corporate 
Management, the target is 75% of the annual base salary 
with a maximum payout factor of 100%.The table below presen